NCT03118297View on ClinicalTrials.gov

Intervention to End Recurrent Unscheduled Bleeding Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
ContraceptionBleeding
Interventions
DRUG

Ulipristal Acetate

Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.

DRUG

Placebo oral capsule

Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.

Trial Locations (1)

63110

Washington University School of Medicine in St. Louis, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT03118297 - Intervention to End Recurrent Unscheduled Bleeding Trial | Biotech Hunter | Biotech Hunter